NCT07361250 (TIS-STN-PD1) is a NA clinical trial of NervioX-1000 in Parkinson Disease, sponsored by Tang Zhouping.

Who is sponsoring NCT07361250?

NCT07361250 is sponsored by Tang Zhouping.

What drugs are being tested in NCT07361250?

Interventions in NCT07361250: NervioX-1000.

What condition does NCT07361250 study?

NCT07361250 studies Parkinson Disease.

Is NCT07361250 still recruiting?

NCT07361250 is currently not yet recruiting. Last updated 22 January 2026.

Last reviewed 2026-01-22 · How we verify

NCT07361250: TIS-STN-PD1

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Subthalamic Nucleus (STN) Targeted Transcranial Temporal Interference Stimulation (TIS) Treats Parkinson's Disease

Not yet recruiting NA Last updated 22 January 2026

What this trial tests

NA trial testing NervioX-1000 in Parkinson Disease in 20 participants. Not yet recruiting.

Timeline

20 January 2026

Primary endpoint
31 December 2026

20 June 2027

Quick facts

Lead sponsor	Tang Zhouping
Phase	NA
Status	Not yet recruiting
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	20
Start date	20 January 2026
Primary completion	31 December 2026
Estimated completion	20 June 2027

Drugs / interventions tested

NervioX-1000

Conditions studied

Parkinson Disease — all drugs for Parkinson Disease →

Sponsor

Tang Zhouping — full company profile →

Who can join

18 and older, any sex, with Parkinson Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a single-center, prospective, double-blind, randomized controlled trial to evaluate the efficacy and safety of transcranial temporal interference stimulation targeting the subthalamic nucleus in patients with Parkinson's disease. It plans to enroll 20 eligible participants who will be randomly assigned in a 1:1 ratio to either the active TIS stimulation group or the sham stimulation group.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Parkinson Disease

Currently open trials in the same condition.

NCT07399496 — Accelerated TMS for Apathy in PD · NA · recruiting
NCT07371338 — Phase 1 Clinical Trial to Evaluate the Safety, Efficacy, and Pharmacokinetics of IPS101A in Parkinson's Disease Patients · Phase 1 · recruiting
NCT07442370 — The Effect of Functional Rotational Exercises on Fall Risk and Mobility in Parkinson's Disease Patients · NA · recruiting
NCT06848205 — Percept Transitions in FOG and PD · NA · recruiting
NCT07432958 — A Study to Evaluate the Effectiveness of Two Doses of AP-472 as Adjunctive Therapy to Levodopa in Parkinson's Disease (P · Phase 2 · recruiting

Other Tang Zhouping trials

Trials by the same sponsor.

NCT06862388 — Stem Cell Therapy for Intracerebral Hemorrhage · Phase 1, PHASE2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07361250 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Tang Zhouping
Last refreshed: 22 January 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07361250.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing